FATE Q1 2024 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-96.7% YoY

Gross Profit

-$3M-150.4% margin

Operating Income

-$51M-2652.9% margin

Net Income

-$48M-2493.7% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+14.9%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$570M

Total Liabilities

$144M

Stockholders' Equity

$426M

Cash & Equivalents

$121M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$59M	-96.7%
Gross Profit	-$3M	-$7M	+56.4%
Operating Income	-$51M	-$29M	-78.6%
Net Income	-$48M	-$19M	-154.2%